New hope for young patients with rare blood disorder
NCT ID NCT07001254
Summary
This study aims to see if adding the drug romiplostim to standard immunosuppressive therapy helps children and young adults (ages 2-21) with severe aplastic anemia. The goal is to improve their blood cell counts and reduce the need for transfusions. The main measure of success is whether patients achieve a complete blood count response after 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.